Garry Nolan Biography and Net Worth

Director of Akoya Biosciences

Garry co-founded Akoya Biosciences in 2015, and is the Rachford and Carlota A. Harris Professor in the Department of Microbiology and Immunology at Stanford University School of Medicine. As a co-inventor of the CODEX technology, Garry has focused his research efforts on developing novel technologies and computational methods for research into cancer, leukemia, immunology and autoimmune disease. Dr. Nolan was the founder of a number of life sciences companies in addition to Akoya, including Rigel Inc. (NASDAQ: RIGL) and DVS Sciences and serves as an advisor and board member for several biotechnology companies. He has published over 220 research articles and is the holder of 20 US patents, and has been honored as one of the top 25 inventors at Stanford University. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore. Garry is the first recipient of the Teal Innovator Award (2012) from the Department of Defense and has been honored with a number of awards including Nature Publishing “Outstanding Research Achievement”, Stohlman Scholar from the Leukemia and Lymphoma Society and Burroughs Wellcome Fund New Investigator Award.

How do I contact Garry Nolan?: The corporate mailing address for Dr. Nolan and other Akoya Biosciences executives is , , . Akoya Biosciences can also be reached via phone at 855-896-8401 and via email at [email protected]. Learn More on Garry Nolan's contact information.
Has Garry Nolan been buying or selling shares of Akoya Biosciences?: Garry Nolan has not been actively trading shares of Akoya Biosciences within the last three months. Learn More on Garry Nolan's trading history.
Who are Akoya Biosciences' active insiders?: Akoya Biosciences' insider roster includes Garry Nolan (Director), Niro Ramachandran (Insider), and Robert Shepler (Director). Learn More on Akoya Biosciences' active insiders.
Are insiders buying or selling shares of Akoya Biosciences?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 30,000 shares worth more than $105,000.00. The most recent insider tranaction occured on June, 11th when CEO Brian Mckelligon sold 7,500 shares worth more than $15,600.00. Insiders at Akoya Biosciences own 7.3% of the company. Learn More about insider trades at Akoya Biosciences.
Information on this page was last updated on 6/11/2024.

Garry Nolan Insider Trading History at Akoya Biosciences

Garry Nolan Buying and Selling Activity at Akoya Biosciences

Akoya Biosciences Company Overview

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Today's Range

Now: $2.49

$2.34

$2.60

50 Day Range

MA: $2.63

$2.07

$3.24

2 Week Range

Now: $2.49

$1.88

$6.31

Volume

365,649 shs

Average Volume

239,451 shs

Market Capitalization

$123.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad